Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD
NCT06657768Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4006895 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 61 weeks. Started Oct 2024; status: recruiting.
02
Drugs
LY4006895
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06657768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657768.